Evaluation of 1-(2-chloroethyl-3-4-methylcyclohexyl)-1-nitrosourea (methyl-CCNU, NSC 95441) versus combined imidazole carboxamide (NSC 45338) and vincristine (NSC 67574) in palliation of disseminated malignant melanoma.
D000577:Amides / Q000009:adverse effects / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001772:Blood Cell Count; D001792:Blood Platelets; D003510:Cyclohexanes; D004064:Digestive System / Q000187:drug effects; D004359:Drug Therapy, Combination; D005069:Evaluation Studies as Topic; D005260:Female; D006413:Hematopoietic System / Q000187:drug effects; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects / Q000627:therapeutic use*; D007958:Leukocyte Count; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009420:Nervous System / Q000187:drug effects; D009607:Nitrosourea Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D010166:Palliative Care; D012878:Skin Neoplasms / Q000188:drug therapy*; D014226:Triazenes / Q000009:adverse effects / Q000627:therapeutic use*; D014750:Vincristine / Q000009:adverse effects / Q000627:therapeutic use*
D000577:Amides; D000970:Antineoplastic Agents; D003510:Cyclohexanes; D007093:Imidazoles; D009607:Nitrosourea Compounds; D014226:Triazenes; D014750:Vincristine